ibrance 100mg capsules
pfizer ltd - palbociclib - capsule - 100mg
ibrance 125mg capsules
pfizer ltd - palbociclib - capsule - 125mg
ibrance
pfizer new zealand limited - palbociclib 100mg - capsule - 100 mg - active: palbociclib 100mg excipient: colloidal silicon dioxide gelatin iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose opacode white s-1-7085 sodium starch glycolate titanium dioxide - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.
ibrance
pfizer new zealand limited - palbociclib 125mg - capsule - 125 mg - active: palbociclib 125mg excipient: colloidal silicon dioxide gelatin iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose opacode white s-1-7085 sodium starch glycolate titanium dioxide - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.
ibrance
pfizer new zealand limited - palbociclib 75mg - capsule - 75 mg - active: palbociclib 75mg excipient: colloidal silicon dioxide gelatin iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose opacode white s-1-7085 sodium starch glycolate titanium dioxide - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.
ibrance capsule
pfizer canada ulc - palbociclib - capsule - 75mg - palbociclib 75mg - antineoplastic agents
ibrance capsule
pfizer canada ulc - palbociclib - capsule - 100mg - palbociclib 100mg - antineoplastic agents
ibrance capsule
pfizer canada ulc - palbociclib - capsule - 125mg - palbociclib 125mg - antineoplastic agents
ibrance tablet
pfizer canada ulc - palbociclib - tablet - 75mg - palbociclib 75mg - antineoplastic agents
ibrance tablet
pfizer canada ulc - palbociclib - tablet - 100mg - palbociclib 100mg - antineoplastic agents